For example, gefitinib, an EGFR inhibitor suppressing tumor growth and angiogenesis, was recently shown to inhibit the crosstalk between macrophages and cancer cells by blocking receptor interacting protein kinase 2 (RIPK2) (164). This evidence concerns the gene EGFR and neoplasm.